ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Regeneron Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-847-7000 Fax: n/a


SEARCH JOBS



Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

Visit our website – www.regeneron.com
Check out our openings – www.careers.regeneron


 Key Statistics


Email:
Ownership: Public

Web Site: Regeneron
Employees: 2300+
Symbol: REGN
 



Industry
Biotechnology


Collaborations

Sanofi US 

Bayer 

Geisinger Health System  Collaboration with Regeneron Genetics Center LLC, wholly-owned subsidiary of Regeneron.

Avalanche Biotechnologies 





 Company News
Regeneron (REGN) and Sanofi (SAN.PA) Partnership Records Another Hit In Latest String of Successes 5/21/2015 6:30:06 AM
Regeneron (REGN) And Sanofi (SAN.PA) Announce Positive Pivotal Phase 2b Dupilumab Data In Asthma Presented At The American Thoracic Society 2015 International Conference 5/18/2015 10:50:21 AM
Regeneron (REGN) Reports First Quarter 2015 Financial And Operating Results 5/7/2015 8:56:53 AM
pSivida (PSDV)'s Drug Delivery Technology Business Model Draws Comparison to Regeneron (REGN) Blockbuster Success 5/5/2015 6:37:44 AM
Regeneron (REGN) Announces Upcoming 2015 Investor Conference Presentations 4/29/2015 12:56:22 PM
Regeneron (REGN) CEO Heads to Cuba With N.Y. Trade Delegation 4/16/2015 6:28:22 AM
Regeneron (REGN) To Report First Quarter 2015 Financial And Operating Results And Host Conference Call And Webcast On May 7, 2015 4/10/2015 11:09:54 AM
Regeneron (REGN) Release: EYLEA (aflibercept) Injection Receives FDA Approval For The Treatment Of Diabetic Retinopathy In Patients With Diabetic Macular Edema (DME) 3/25/2015 9:16:56 AM
Filing Shows Regeneron (REGN) Stopped Paying CEO and CSO's Club Membership Fees 3/23/2015 6:05:01 AM
Sanofi (SAN.PA), Regeneron (REGN): 18-Month Results Of ODYSSEY LONG TERM Trial With Praluent (Alirocumab) Published In The New England Journal of Medicine 3/16/2015 6:01:28 AM
12345678910...